Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TADCOM: Carbon Marking for Targeted Axillary Dissection
NCT04744506Recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Nov 2024
- Primary completion
- Jul 2028
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Randomised, open-label trial of Kanarine in breast cancer (3 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Lymph node retrieval rate marked at 2 months, Number of sentinel and marked lymph nodes at 2 months and 2 more. Started Nov 2024; status: recruiting.
02
Drugs
Kanarine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04744506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04744506.